© 2015 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934 eISSN 1598-6357 http://dx.doi.org/10.3346/jkms.2015.30.9.1373 • J Korean Med Sci 2015; 30: 1373
CORRESPONDENCE
Erratum: A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease
Jin-Ho Choi, Beom Hee Lee, Jung Min Ko, Young Bae Sohn, Jin-Sung Lee, Gu-Hwan Kim, Sun Hee Heo, June-Young Park, Yoo-Mi Kim, Ja-Hye Kim, and Han-Wook Yoo
To the Editor:
The authors want to clarify the definition of “biosimilar” based on “Regulatory expectations and risk assessment for biotherapeutic products. World Health Organization 2014. available from http://www.who.int/biologicals/WHO_Risk_Assessment_for_Biothera
peutics_1st_PC_24_Jan_2014.pdf”
In this article (J Korean Med Sci 2015;30:378384), as Abcertin® does not meet the exact definition of biosimilar, the authors would like to delete the phrases “a biosimilar of imiglucerase” in Page 379 and “a new biosimilar to imiglucerase” in Page 382.
Thank you.
Sincerely yours, Yoo HW
Address for Correspondence:
Han-Wook Yoo, MD
Department of Pediatrics, Asan Medical Center Children’s Hospital, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea Tel.: +82.2 3010 3374, Fax: +82.2 473 3725, E-mail: [email protected]
